Last reviewed · How we verify

Kepivance (Palifermin) — Competitive Intelligence Brief

Kepivance (Palifermin) (Kepivance (Palifermin)) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Fibroblast growth factor (FGF) receptor agonist. Area: Oncology.

marketed Fibroblast growth factor (FGF) receptor agonist FGFR2 (Fibroblast Growth Factor Receptor 2) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Kepivance (Palifermin) (Kepivance (Palifermin)) — Swedish Orphan Biovitrum. Palifermin is a recombinant human fibroblast growth factor 7 (FGF-7) that stimulates epithelial cell proliferation and differentiation to promote healing of damaged mucous membranes.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Kepivance (Palifermin) TARGET Kepivance (Palifermin) Swedish Orphan Biovitrum marketed Fibroblast growth factor (FGF) receptor agonist FGFR2 (Fibroblast Growth Factor Receptor 2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Fibroblast growth factor (FGF) receptor agonist class)

  1. Swedish Orphan Biovitrum · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Kepivance (Palifermin) — Competitive Intelligence Brief. https://druglandscape.com/ci/kepivance-palifermin. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: